Moderna expects at least $19 billion in Covid vaccine sales in 2022, reports big fourth-quarter earnings beat
Published
Moderna beat on its top and bottom lines, reporting earnings per share of $11.29 and revenue of $7.2 billion.
Full ArticlePublished
Moderna beat on its top and bottom lines, reporting earnings per share of $11.29 and revenue of $7.2 billion.
Full ArticleModerna’s COVID-19 vaccine brought in nearly $7 billion in the final quarter of 2021, and the drugmaker says it has signed..
The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker’s COVID-19 treatment..
Stocks that traded heavily or had substantial price changes Monday:
Citrix Systems Inc., down $3.61 to..